Global Information
회사소개 | 문의

신장암 : 파이프라인 리뷰

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 06월 상품 코드 229726
페이지 정보 영문 1663 Pages
가격
US $ 2,500 ₩ 2,822,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,644,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,466,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


신장암 : 파이프라인 리뷰 Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2018
발행일 : 2018년 06월 페이지 정보 : 영문 1663 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

신장암은 신장세포가 악성화하여 암이 되어 제어할수 없게 되고 종양을 발생하게 하는 질환입니다. 증상으로는 혈뇨, 식욕 부진, 몇 주간 지속되는 열, 심한 피로감, 빈혈, 헐떡임, 뼈의 통증 등이 있습니다. 치료법은 외과적 수술, 방사선 치료, 화학요법 등입니다.

신장암(Kidney Cancer) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업이나 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 최신 뉴스 및 발표와 함께 전해드립니다.

1. 서론

  • 신장암 개요

2. 치료제 개발

3. 기업에서 개발중인 치료제

4. 대학/기관에서 연구중인 치료제

5. 파이프라인 제품 개요

6. 기업에서 개발중인 제품

7. 대학/기관에서 연구중인 제품

8. 치료제 개발에 종사하고 있는 기업

9. 치료제 평가

10. 치료제 개요

11. 최근의 파이프라인 동향

12. 휴지 상태인 프로젝트

13. 개발이 중지된 제품

14. 제품 개발 마일스톤

15. 부록

LSH 15.08.20

List of Tables

  • Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by 4D Pharma PLC, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by 4SC AG, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by AbbVie Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Actuate Therapeutics Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Aduro BioTech Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Advanced Cancer Therapeutics LLC, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Advenchen Laboratories LLC, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Affitech A/S, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Alethia Biotherapeutics Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Alkermes Plc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Altor BioScience Corp, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Ambrx Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Amgen Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Ampio Pharmaceuticals Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Apac Biotech Pvt Ltd, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Apcure SAS, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by APEIRON Biologics AG, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Apexigen Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Aphios Corp, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Arcus Biosciences Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by arGEN-X BV, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by ARMO Biosciences Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by ArQule Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Astellas Pharma Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by AstraZeneca Plc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Atreca Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Bayer AG, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by BeiGene Ltd, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Biocad, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by BioClin Therapeutics Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionomics Ltd, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Biotest AG, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Calithera Biosciences Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by CASI Pharmaceuticals Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by CBT Pharmaceuticals Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Celgene Corp, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Celldex Therapeutics Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Cellular Biomedicine Group Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Celyad SA, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Checkpoint Therapeutics Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Chipscreen Biosciences Ltd, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Clovis Oncology Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by COARE Biotechnology Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Coherus BioSciences Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Corvus Pharmaceuticals Inc, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by CRISPR Therapeutics, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Ecrins Therapeutics SAS, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Eisai Co Ltd, H1 2018
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Eli Lilly and Co, H1 2018

List of Figures

  • Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018

영문목차

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2018, provides an overview of the Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline landscape.

Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 16, 111, 91, 4, 80, 14 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 13, 8 and 16 molecules, respectively.

Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Kidney Cancer (Renal Cell Cancer) - Overview
  • Kidney Cancer (Renal Cell Cancer) - Therapeutics Development
  • Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment
  • Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development
  • Kidney Cancer (Renal Cell Cancer) - Drug Profiles
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects
  • Kidney Cancer (Renal Cell Cancer) - Discontinued Products
  • Kidney Cancer (Renal Cell Cancer) - Product Development Milestones
  • Appendix
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research